BioPoly LLC Receives Innovative Technology Contract from Vizient
General
July 18, 2025
BioPoly LLC Receives Innovative Technology Contract from Vizient for Its FDA Cleared Implant Systems
Contract awarded for products that bring improvement to healthcare industry
Fort Wayne, Indiana, July 18, 2025– BioPoly, LLC announced its innovative synthetic cartilage implant product lines (BioPoly® Great Toe, Lesser Toes, Radial Head) have received an Innovative Technology contract from Vizient, Inc. the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on review of BioPoly’s Implant Systems from hospital experts who serve on one of Vizient’s client-led councils, and it signifies to Vizient clients its unique qualities that potentially bring improvement to the healthcare industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient client-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations.
“We’re honored to be awarded this contract with Vizient.” said Herb Schwartz, President and CEO of BioPoly LLC. “This agreement represents a major milestone in expanding access to our BioPoly® implants, allowing Vizient client hospitals across the U.S. to offer our innovative, joint-preserving solutions.”
BioPoly® implants are engineered from a proprietary microcomposite material that integrates ultra-high molecular weight polyethylene (UHMWPE) with hyaluronic acid, resulting in a biomaterial designed to emulate the low-friction, load-bearing characteristics of native cartilage. Unlike conventional metal implants, BioPoly® devices are uniquely formulated to interact synergistically with the surrounding cartilage surfaces, supporting natural biomechanics and promoting joint preservation. With this Vizient contract, participating hospitals can now adopt BioPoly’s advanced implant systems to deliver differentiated treatment options that aim to improve long-term patient outcomes.
“After a full review of the BioPoly synthetic cartilage implants, Vizient’s client-led council agreed this solution offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to BioPoly,” said Kelly Flaharty, senior director of contract services for Vizient.
Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with client-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.
About: BioPoly
